Search results
Results from the Tech24 Deals Content Network
August 8, 2024 at 11:52 AM. Shares of Viatris (NASDAQ: VTRS) were jumping 6% higher as of 11:18 a.m. ET on Thursday after rising as much as 12.4% earlier in the day. The solid gain came after the ...
Viatris (VTRS) closed the most recent trading day at $15.17, moving -0.98% from the previous trading session.
You should check […] Mittleman Investment Management’s composite gained 25.9% net of fees in the first quarter of 2021, versus gains of 6.2% in the S&P 500 Total Return Index and 12.7% in the ...
Viatris also reaffirmed its full-revenue revenue forecast to the range of $15.5 billion to $16 billion, compared to analysts' estimates of $15.60 billion. Excluding items, the company reported a ...
Until recently, Viatris (NASDAQ:VTRS) was considered a value play among drug stocks. But after its recent earnings report, and announced sale of a key asset? The generic drug maker has been deemed ...
When it made its debut last November, Viatris (VTRS) was touted as a value-unlocking divestiture. The pharmaceutical company, formed when Pfizer (PFE) merged its Upjohn unit with Mylan NV, started ...
Viatris was formed with the merger of Mylan and Pfizer's Upjohn business and has generic and key branded drugs in its portfolio, including erectile dysfunction drug Viagra, anti-anxiety medication ...
The receipt of the FDA's letter would not impact Viatris' 2024 forecast or its new product revenue range of $450 million to $550 million, the company said. In MS, the immune system attacks brain ...